Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways : Drugs that Target the Stemness PathwaysTAKEBE, Naoko; IVY, S. Percy.Clinical cancer research (Print). 2010, Vol 16, Num 12, pp 3106-3112, issn 1078-0432, 7 p.Article

Detection of P-glycoprotein in cell lines and leukemic blasts : failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cellsTAYLOR, Barbara J; OLSON, Douglas P; IVY, S. Percy et al.Leukemia research. 2001, Vol 25, Num 12, pp 1127-1135, issn 0145-2126Article

Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee : CCRIVY, S. Percy; SIU, Lillian L; GARRETT-MAYER, Elizabeth et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1726-1736, issn 1078-0432, 11 p.Article

Design issues of randomized phase II trials and a proposal for phase II screening trialsRUBINSTEIN, Lawrence V; KORN, Edward L; FREIDLIN, Boris et al.Journal of clinical oncology. 2005, Vol 23, Num 28, pp 7199-7206, issn 0732-183X, 8 p.Article

A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinomaBRELL, Joanna M; KRISHNAMURTHI, Smitha S; IVY, S. Percy et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 5, pp 851-857, issn 0344-5704, 7 p.Article

A Phase I Study of17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid MalignanciesRAMALINGAM, Suresh S; EGORIN, Merrill J; IVY, S. Percy et al.Clinical cancer research. 2008, Vol 14, Num 11, pp 3456-3461, issn 1078-0432, 6 p.Article

Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRAMANATHAN, Ramesh K; FAKIH, Marwan; PARISE, Robert A et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 465-474, issn 0344-5704, 10 p.Article

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabineKRISHNAMURTHI, Smitha S; BRELL, Joanna M; COONEY, Matthew M et al.Cancer chemotherapy and pharmacology. 2009, Vol 63, Num 3, pp 441-450, issn 0344-5704, 10 p.Article

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction : A Study by the National Cancer Institute Organ Dysfunction Working GroupGIBBONS, Joseph; EGORIN, Merrill J; PAVLICK, Anna et al.Journal of clinical oncology. 2008, Vol 26, Num 4, pp 570-576, issn 0732-183X, 7 p.Article

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRAMANATHAN, Ramesh K; TRUMP, Donald L; BRUFSKY, Adam M et al.Clinical cancer research. 2005, Vol 11, Num 9, pp 3385-3391, issn 1078-0432, 7 p.Article

Developing Standards for Breakthrough Therapy Designation in OncologyHORNING, Sandra J; HABER, Daniel A; SELIG, Wendy K. D et al.Clinical cancer research (Print). 2013, Vol 19, Num 16, pp 4297-4304, issn 1078-0432, 8 p.Article

Phase i pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors : A pediatric oncology experimental therapeutics investigators consortium studyBAGATELL, Rochelle; GORE, Lia; KATZENSTEIN, Howard M et al.Clinical cancer research. 2007, Vol 13, Num 6, pp 1783-1788, issn 1078-0432, 6 p.Article

Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxyl-propionic acid; NSC698215) in patients and in vitro : low potential for active or toxic metabolites or for drug-drug interactionsANDERSON, Lawrence W; COLLINS, Jerry M; KLECKER, Raymond W et al.Cancer chemotherapy and pharmacology. 2005, Vol 56, Num 4, pp 351-357, issn 0344-5704, 7 p.Article

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)RICHTER, Suzanne; BEDARD, Philippe L; ZHUO CHEN et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 243-249, issn 0167-6997, 7 p.Article

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsSPREAFICO, Anna; CHI, Kim N; KOLLMANNSBERGER, Christian K et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 1005-1016, issn 0167-6997, 12 p.Article

Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteePALLER, Channing J; BRADBURY, Penelope A; REEVES, Steven et al.Clinical cancer research (Print). 2014, Vol 20, Num 16, pp 4210-4217, issn 1078-0432, 8 p.Article

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignanciesKUMMAR, Shivaani; GUTIERREZ, Martin E; HORNEFFER, Yvonne R et al.European journal of cancer (1990). 2010, Vol 46, Num 2, pp 340-347, issn 0959-8049, 8 p.Article

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee : CCRSEYMOUR, Lesley; IVY, S. Percy; GROSHEN, Susan et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1764-1769, issn 1078-0432, 6 p.Article

Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II TrialsPHILIP, Philip A; CHANSKY, Kari; LEBLANC, Michael et al.Clinical cancer research (Print). 2014, Vol 20, Num 16, pp 4176-4185, issn 1078-0432, 10 p.Article

Cediranib for Metastatic Alveolar Soft Part SarcomaKUMMAR, Shivaani; ALLEN, Deborah; SIMON, Richard et al.Journal of clinical oncology. 2013, Vol 31, Num 18, pp 2296-2302, issn 0732-183X, 7 p.Article

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyRAMALINGAM, Suresh S; KUMMAR, Shivaani; IVY, S. Percy et al.Journal of clinical oncology. 2010, Vol 28, Num 29, pp 4507-4512, issn 0732-183X, 6 p.Article

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction : A Study by the National Cancer Institute Organ Dysfunction Working GroupRAMANATHAN, Ramesh K; EGORIN, Merrill J; POTTER, Douglas M et al.Journal of clinical oncology. 2008, Vol 26, Num 4, pp 563-569, issn 0732-183X, 7 p.Article

A phase I study of 17-allylaminogeldanamycin in relapsed/ refractory pediatric patients with solid tumors : A children's oncology group studyWEIGEL, Brenda J; BLANEY, Susan M; GILBERTSON, Richard J et al.Clinical cancer research. 2007, Vol 13, Num 6, pp 1789-1793, issn 1078-0432, 5 p.Article

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancersRAMANATHAN, Ramesh K; EGORIN, Merrill J; STOLLER, Ronald G et al.Clinical cancer research. 2007, Vol 13, Num 6, pp 1769-1774, issn 1078-0432, 6 p.Article

First-in-Human Phase 0 Trial of Oral 5-lodo-2-Pyrimidinone-2'-Deoxyribose in Patients with Advanced MalignanciesKUMMAR, Shivaani; ANDERSON, Larry; COLLINS, Jerry M et al.Clinical cancer research (Print). 2013, Vol 19, Num 7, pp 1852-1857, issn 1078-0432, 6 p.Article